Abivax S.A. Increase Decrease Through Other Changes Liabilities Arising From Financing Activities
Abivax S.A. (ABVX) reported Increase Decrease Through Other Changes Liabilities Arising From Financing Activities of EUR 17.20 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities · last filed 2026-03-23
- Abivax S.A. increase decrease through other changes liabilities arising from financing activities for the quarter ending 2025-12-31 was 3.99M EUR, a 17.83% decline year-over-year.
- Abivax S.A. increase decrease through other changes liabilities arising from financing activities for the quarter ending 2025-09-30 was 5.15M EUR, a 8.60% increase year-over-year.
- Abivax S.A. increase decrease through other changes liabilities arising from financing activities for the quarter ending 2025-06-30 was 3.52M EUR, a 8.31% decline year-over-year.
- Abivax S.A. increase decrease through other changes liabilities arising from financing activities for the quarter ending 2025-03-31 was 4.54M EUR, a 89.59% increase year-over-year.
| Period end | Increase Decrease Through Other Changes Liabilities Arising From Financing Activities 3 month | Increase Decrease Through Other Changes Liabilities Arising From Financing Activities 6 month | Increase Decrease Through Other Changes Liabilities Arising From Financing Activities 9 month | Increase Decrease Through Other Changes Liabilities Arising From Financing Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | 3.99M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-03-23 | 9.14M EUR derived: sum of 2 quarters · filed 2026-03-23 | 12.66M EUR derived: sum of 3 quarters · filed 2026-03-23 | 17.20M EUR 20-F · filed 2026-03-23 |
| 2025-09-30 | 5.15M EUR derived: 6-K 9 month − 6-K 6 month · filed 2025-12-15 | 8.67M EUR derived: sum of 2 quarters · filed 2025-12-15 | 13.21M EUR 6-K · filed 2025-12-15 | 18.07M EUR derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-06-30 | 3.52M EUR derived: 6-K 6 month − 6-K 3 month · filed 2025-09-08 | 8.06M EUR 6-K · filed 2025-09-08 | 12.91M EUR derived: sum of 3 quarters · filed 2026-03-23 | 17.66M EUR derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-03-31 | 4.54M EUR 6-K · filed 2025-06-02 | 9.39M EUR derived: sum of 2 quarters · filed 2026-03-23 | 14.14M EUR derived: sum of 3 quarters · filed 2026-03-23 | 17.98M EUR derived: sum of 4 quarters · filed 2026-03-23 |
| 2024-12-31 | 4.86M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-03-23 | 9.60M EUR derived: sum of 2 quarters · filed 2026-03-23 | 13.44M EUR derived: sum of 3 quarters · filed 2026-03-23 | 15.83M EUR 20-F · filed 2026-03-23 |
| 2024-09-30 | 4.75M EUR derived: 6-K 9 month − 6-K 6 month · filed 2025-12-15 | 8.59M EUR derived: sum of 2 quarters · filed 2025-12-15 | 10.98M EUR 6-K · filed 2025-12-15 | |
| 2024-06-30 | 3.84M EUR derived: 6-K 6 month − 6-K 3 month · filed 2025-09-08 | 6.23M EUR 6-K · filed 2025-09-08 | ||
| 2024-03-31 | 2.39M EUR 6-K · filed 2025-06-02 | |||
| 2023-12-31 | 7.46M EUR 20-F · filed 2026-03-23 | |||
| 2022-12-31 | 6.98M EUR 20-F · filed 2025-03-24 | |||
| 2021-12-31 | 1.52M EUR 20-F · filed 2024-04-05 |